Stay updated on Pembrolizumab for Intermediate Risk NMIBC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for Intermediate Risk NMIBC Clinical Trial page.

Latest updates to the Pembrolizumab for Intermediate Risk NMIBC Clinical Trial page
- Check2 days agoChange DetectedAdded 'Bladder cancer' as a related topic and added 'MedlinePlus Genetics' as a related topic.SummaryDifference0.2%

- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedRevision: v3.5.0 has been added and the previous Revision: v3.4.3 has been removed.SummaryDifference0.1%

- Check23 days agoChange DetectedRemoved the 'Bladder cancer' topic and the 'MedlinePlus Genetics' related topics from the page.SummaryDifference0.2%

- Check30 days agoChange DetectedRevision: v3.4.3 was added. Revision: v3.4.2 was removed.SummaryDifference0.1%

- Check37 days agoChange Detected- Added related topics: Bladder cancer and MedlinePlus Genetics to the page.SummaryDifference0.2%

- Check51 days agoChange DetectedThe page now lists Revision: v3.4.2 and no longer lists Revision: v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab for Intermediate Risk NMIBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Intermediate Risk NMIBC Clinical Trial page.